| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics, Inc. | 1.92B | 39.81 | 511.70 | 31.18% | -33.24% | 3.91% | 0.14 | |
| GNFTGenfit S.A. | 313.52M | 6.27 | 209 | 134.56% | -14.12% | -31.42% | 4.54% | 0.90 |
| GYREGyre Therapeutics, Inc. | 741.77M | 7.70 | 154 | -6.78% | 6.2% | 4.84% | 0.02 | |
| TVRDTvardi Therapeutics, Inc. | 42.31M | 4.51 | -0.10 | -65.96% | -317.54% | -63.46% | ||
| UNCYUnicycive Therapeutics, Inc. | 134.75M | 6.27 | -1.12 | -100% | -89.15% | 0.10 | ||
| GLTOGalecto, Inc. | 38.32M | 23.95 | -1.29 | -237.68% | 0.00 | |||
| IVAInventiva S.A. | 1.17B | 6.12 | -1.73 | -47.37% | -13.75% | |||
| AKBAAkebia Therapeutics, Inc. | 355.59M | 1.34 | -4.06 | -17.7% | -7.07% | -38.24% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 19.14M | 77.06M | 186.37M | 336.89M |
| Revenue Growth % | - | - | - | - | 3.03% | 1.42% | 0.81% |
| Cost of Goods Sold | 0 | 324K | 623K | 1.9M | 12.37M | 47.04M | 81.64M |
| COGS % of Revenue | - | - | - | 0.1% | 0.16% | 0.25% | 0.24% |
| Gross Profit | 0 | -324K | -623K | 17.23M | 64.69M | 139.34M | 255.25M |
| Gross Margin % | - | - | - | 0.9% | 0.84% | 0.75% | 0.76% |
| Gross Profit Growth % | - | - | -0.92% | 28.66% | 2.75% | 1.15% | 0.83% |
| Operating Expenses | 2.92M | 54.74M | 103.67M | 190.65M | 195.91M | 248.49M | 342.85M |
| OpEx % of Revenue | - | - | - | 9.96% | 2.54% | 1.33% | 1.02% |
| Selling, General & Admin | 585K | 11.75M | 22.69M | 59.22M | 89.07M | 145.88M | 202.22M |
| SG&A % of Revenue | - | - | - | 3.09% | 1.16% | 0.78% | 0.6% |
| Research & Development | 2.33M | 42.99M | 81.61M | 131.43M | 106.84M | 102.61M | 140.63M |
| R&D % of Revenue | - | - | - | 6.87% | 1.39% | 0.55% | 0.42% |
| Other Operating Expenses | 0 | -21K | -623K | 0 | 0 | 0 | 0 |
| Operating Income | -2.92M | -54.74M | -104.3M | -173.41M | -131.22M | -109.15M | -87.61M |
| Operating Margin % | - | - | - | -9.06% | -1.7% | -0.59% | -0.26% |
| Operating Income Growth % | - | -17.77% | -0.91% | -0.66% | 0.24% | 0.17% | 0.2% |
| EBITDA | 1.46M | -54.42M | -103.67M | -172.44M | -127.98M | -98.33M | -63.98M |
| EBITDA Margin % | - | - | - | -9.01% | -1.66% | -0.53% | -0.19% |
| EBITDA Growth % | - | -38.32% | -0.91% | -0.66% | 0.26% | 0.23% | 0.35% |
| D&A (Non-Cash Add-back) | 4.37M | 324K | 623K | 975K | 3.24M | 10.83M | 23.63M |
| EBIT | -17.33M | -52.53M | -102.93M | -66.36M | -126.09M | -147.32M | -72.6M |
| Net Interest Income | 0 | 2.23M | 1.22M | -17.22M | -12.12M | -1.37M | -519K |
| Interest Income | 87K | 2.23M | 1.56M | 366K | 3.86M | 13.73M | 13.79M |
| Interest Expense | 0 | 0 | 335K | 17.59M | 15.98M | 15.11M | 14.31M |
| Other Income/Expense | -14.43M | 2.21M | 1.03M | 89.46M | -10.85M | -53.27M | 694K |
| Pretax Income | -17.35M | -52.53M | -103.26M | -83.95M | -142.07M | -162.42M | -86.91M |
| Pretax Margin % | - | - | - | -4.39% | -1.84% | -0.87% | -0.26% |
| Income Tax | 0 | 21K | 6K | 37K | -6.41M | 991K | 1.03M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 0.95% | 1.01% | 1.01% |
| Net Income | -17.35M | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M |
| Net Margin % | - | - | - | -4.39% | -1.76% | -0.88% | -0.26% |
| Net Income Growth % | - | -2.03% | -0.97% | 0.19% | -0.62% | -0.2% | 0.46% |
| Net Income (Continuing) | -17.35M | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.75 | -2.29 | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 |
| EPS Growth % | - | -2.05% | -0.79% | 0.32% | -0.45% | 0% | 0.54% |
| EPS (Basic) | -0.75 | -2.29 | -4.09 | -2.77 | -4.01 | -4.00 | -1.85 |
| Diluted Shares Outstanding | 22.99M | 22.99M | 25.25M | 30.32M | 33.98M | 40.89M | 47.52M |
| Basic Shares Outstanding | 22.99M | 22.99M | 25.25M | 30.32M | 33.84M | 40.89M | 47.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.98M | 119.36M | 236.35M | 166.59M | 190.22M | 387.54M | 392.79M |
| Cash & Short-Term Investments | 51.96M | 116.66M | 231.82M | 156.54M | 151.72M | 286.33M | 280.31M |
| Cash Only | 51.96M | 11.97M | 142.09M | 31.34M | 28M | 286.33M | 222.5M |
| Short-Term Investments | 0 | 104.69M | 89.73M | 125.2M | 123.72M | 0 | 57.81M |
| Accounts Receivable | 0 | 0 | 0 | 3.27M | 23.99M | 67.97M | 78.29M |
| Days Sales Outstanding | - | - | - | 62.31 | 113.65 | 133.11 | 84.82 |
| Inventory | 0 | 0 | 0 | 1.51M | 5.57M | 22.31M | 22.4M |
| Days Inventory Outstanding | - | - | - | 290.2 | 164.15 | 173.13 | 100.16 |
| Other Current Assets | 12K | 0 | 0 | 0 | 8.95M | 10.94M | 11.78M |
| Total Non-Current Assets | 0 | 27.35M | 4.51M | 128.06M | 162.68M | 259.08M | 277.97M |
| Property, Plant & Equipment | 0 | 3.73M | 3.24M | 2.55M | 2.35M | 1.99M | 9.81M |
| Fixed Asset Turnover | - | - | - | 7.51x | 32.86x | 93.66x | 34.33x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 18.74M | 58.95M | 252.93M | 249.82M |
| Long-Term Investments | 0 | 23.29M | 0 | 4.98M | 0 | 0 | 12.53M |
| Other Non-Current Assets | 0 | 324K | 1.27M | 101.79M | 101.38M | 4.17M | 5.81M |
| Total Assets | 51.98M | 146.71M | 240.86M | 294.65M | 352.91M | 646.62M | 670.75M |
| Asset Turnover | - | - | - | 0.06x | 0.22x | 0.29x | 0.50x |
| Asset Growth % | - | 1.82% | 0.64% | 0.22% | 0.2% | 0.83% | 0.04% |
| Total Current Liabilities | 2.45M | 13.08M | 18.46M | 42.6M | 64.73M | 87.06M | 126.55M |
| Accounts Payable | 269K | 3.35M | 3.15M | 9.17M | 8.69M | 7.42M | 14.62M |
| Days Payables Outstanding | - | 3.78K | 1.85K | 1.76K | 256.33 | 57.54 | 65.35 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15K | 2.22M | 6.07M | 11.98M | 15.75M | 20.94M | 32.25M |
| Current Ratio | 21.22x | 9.13x | 12.80x | 3.91x | 2.94x | 4.45x | 3.10x |
| Quick Ratio | 21.22x | 9.13x | 12.80x | 3.88x | 2.85x | 4.19x | 2.93x |
| Cash Conversion Cycle | - | - | - | -1.41K | 21.47 | 248.7 | 119.62 |
| Total Non-Current Liabilities | 59.85M | 3.29M | 50.31M | 131.84M | 146.14M | 310.89M | 318.56M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 306.42M | 308.08M |
| Capital Lease Obligations | 0 | 3.25M | 2.63M | 1.9M | 1.26M | 617K | 7.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 59.85M | 36K | 29K | 17K | 4.53M | 3.85M | 2.51M |
| Total Liabilities | 62.3M | 16.36M | 68.77M | 174.44M | 210.87M | 397.95M | 445.11M |
| Total Debt | 0 | 3.65M | 3.26M | 2.61M | 2.19M | 308.14M | 317.76M |
| Net Debt | -51.96M | -8.32M | -138.82M | -28.73M | -25.82M | 21.82M | 95.26M |
| Debt / Equity | - | 0.03x | 0.02x | 0.02x | 0.02x | 1.24x | 1.41x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -35.64x | - | - | - | - | - | - |
| Interest Coverage | - | - | -311.33x | -9.86x | -8.21x | -7.23x | -6.12x |
| Total Equity | -10.32M | 130.35M | 172.09M | 120.21M | 142.04M | 248.67M | 225.64M |
| Equity Growth % | - | 13.63% | 0.32% | -0.3% | 0.18% | 0.75% | -0.09% |
| Book Value per Share | -0.45 | 5.67 | 6.82 | 3.96 | 4.18 | 6.08 | 4.75 |
| Total Shareholders' Equity | -10.32M | 130.35M | 172.09M | 120.21M | 142.04M | 248.67M | 225.64M |
| Common Stock | 6.99M | 2K | 3K | 3K | 4K | 5K | 5K |
| Retained Earnings | -17.35M | -69.9M | -173.17M | -257.16M | -392.82M | -556.24M | -644.18M |
| Treasury Stock | 66.81M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -66.84M | 129K | 83K | -35K | -217K | 1.64M | -373K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -373K | -39.36M | -89.08M | -132.76M | -120.14M | -70.94M | 10.32M |
| Operating CF Margin % | - | - | - | -6.94% | -1.56% | -0.38% | 0.03% |
| Operating CF Growth % | - | -104.53% | -1.26% | -0.49% | 0.1% | 0.41% | 1.15% |
| Net Income | -17.35M | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M |
| Depreciation & Amortization | 0 | 324K | 623K | 975K | 3.68M | 10.83M | 23.63M |
| Stock-Based Compensation | 51K | 6.07M | 12.55M | 23.09M | 27.01M | 35.02M | 48.44M |
| Deferred Taxes | 0 | 0 | 72K | 595K | -6.58M | 0 | 0 |
| Other Non-Cash Items | 12.09M | -326K | 335K | -90.41M | 12.47M | 69.26M | 3.6M |
| Working Capital Changes | 2.44M | 7.12M | 611K | 16.98M | -21.05M | -22.64M | 22.59M |
| Change in Receivables | 0 | 0 | 0 | 0 | -20.73M | -43.97M | -11.43M |
| Change in Inventory | 0 | 0 | 0 | -495K | -3.45M | -4.39M | -3.17M |
| Change in Payables | 2.45M | 10.06M | 3.68M | 22.66M | 7.64M | 30.78M | 40.31M |
| Cash from Investing | -7.5M | -127.78M | 37.87M | 48.55M | 7.7M | -107.2M | -90.13M |
| Capital Expenditures | -7.5M | -281K | -225K | -19.02M | -278K | -109K | -993K |
| CapEx % of Revenue | - | - | - | 0.99% | 0% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -11.25M | -127.5M | 38.1M | 127M | 7.98M | -20M | -20M |
| Cash from Financing | 59.84M | 127.18M | 181.29M | 73.47M | 109.09M | 336.6M | 17.7M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 49.42M | 66.55M | 1.72M | -185.39M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -7.87M | -39.64M | -89.3M | -151.78M | -120.41M | -91.05M | 9.33M |
| FCF Margin % | - | - | - | -7.93% | -1.56% | -0.49% | 0.03% |
| FCF Growth % | - | -4.04% | -1.25% | -0.7% | 0.21% | 0.24% | 1.1% |
| FCF per Share | -0.34 | -1.72 | -3.54 | -5.01 | -3.54 | -2.23 | 0.20 |
| FCF Conversion (FCF/Net Income) | 0.02x | 0.75x | 0.86x | 1.58x | 0.89x | 0.43x | -0.12x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 6.82M | 12.65M |
| Taxes Paid | 0 | 21K | 11K | 0 | 0 | 125K | 1M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -87.57% | -68.29% | -57.47% | -103.46% | -83.65% | -37.08% |
| Return on Invested Capital (ROIC) | - | -137.45% | -100.74% | -208.5% | -94.76% | -42.34% | -22.22% |
| Gross Margin | - | - | - | 90.06% | 83.94% | 74.76% | 75.77% |
| Net Margin | - | - | - | -438.85% | -176.05% | -87.68% | -26.1% |
| Debt / Equity | - | 0.03x | 0.02x | 0.02x | 0.02x | 1.24x | 1.41x |
| Interest Coverage | - | - | -311.33x | -9.86x | -8.21x | -7.23x | -6.12x |
| FCF Conversion | 0.02x | 0.75x | 0.86x | 1.58x | 0.89x | 0.43x | -0.12x |
| Revenue Growth | - | - | - | - | 302.66% | 141.85% | 80.76% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Product | 3.14M | 75.06M | 178.87M | 336.41M |
| Product Growth | - | 2292.03% | 138.30% | 88.07% |
| License and Other Revenue | - | - | - | 479K |
| License and Other Revenue Growth | - | - | - | - |
| License Revenue | - | - | 7.5M | - |
| License Revenue Growth | - | - | - | - |
| License | 16M | 2M | - | - |
| License Growth | - | -87.50% | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | - | - | 146.7M | 274.17M |
| UNITED STATES Growth | - | - | - | 86.89% |
| the World | - | - | - | 62.24M |
| the World Growth | - | - | - | - |
| World | - | - | 32.17M | - |
| World Growth | - | - | - | - |
Mirum Pharmaceuticals, Inc. (MIRM) reported $471.8M in revenue for fiscal year 2024.
Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 80.8% over the past year. This is strong growth.
Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $41.4M for fiscal year 2024.
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity (ROE) of -37.1%. Negative ROE indicates the company is unprofitable.
Mirum Pharmaceuticals, Inc. (MIRM) generated $44.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.